Xeloda

(Capecitabine)

Phase 3Small molecule

Capecitabine is used to treat certain types of cancer, including colorectal cancer and breast cancer. It works by slowing or stopping the growth of cancer cells in the body.[1] Xeloda is currently being investigated across 122 indications[3], with its most advanced program in Phase 3.[1]

Xeloda is one of 1428 small molecule programs targeting Glioma. It is currently in Phase 3.

122

Indications

1,334

Total Trials

Active Trials

1,427

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Pancreatic CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Peritoneum CancerActive, not recruiting

Bone MetastasisActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

MetastasisActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

GliomaPhase 2

Active, not recruiting

Pancreatic CarcinomaPhase 2

Active, not recruiting

Pancreatic NeoplasmPhase 3

Active, not recruiting

Peritoneum CancerPhase 2

Active, not recruiting

Bone MetastasisPhase 1/Phase 2

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Colorectal CarcinomaPhase 3

Active, not recruiting

MetastasisPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Esophageal CarcinomaPhase 3

Active, not recruiting

Showing 10 of 122 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Halaven

38 3

Tecentriq

Roche

Preclinical

36 4

Trodelvy

Gilead

Preclinical

37 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Locally-Advanced Rectal Cancer

NCT06017583

Phase 1Active, not recruiting

Colorectal Cancer

NCT01061515

Q4 2026

Phase 2Active, not recruiting

Capecitabine

NCT03448835

Phase 2Not yet recruiting

Capecitabine

NCT06699459

Phase 2Recruiting

Locally-Advanced Rectal Cancer

NCT05136326

Phase 2Recruiting

Locally-Advanced Rectal Cancer

NCT05731726

Clinical

Trials by Indication[1]

Breast Cancer40 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Recruiting· Roche logo

Roche·Phase 1/2·NCT03424005·792 enrolled

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05840211·654 enrolled

Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

Terminated·HHoosier Cancer Research Network·Phase 2·NCT00216073·11 enrolled

Show 37 more trials

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Unknown status·—·Phase 2·NCT04571437·204 enrolled

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00129935·1,384 enrolled

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00070252·53 enrolled

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT06942234·180 enrolled

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

Unknown status·CConsorzio Oncotech·Phase 2·NCT05833919·122 enrolled

Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00270491·130 enrolled

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Completed·RR-Pharm·Phase 3·NCT00082433·1,221 enrolled

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04895358·340 enrolled

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Unknown status·AAdherex Technologies, Inc.·Phase 2·NCT01231802·140 enrolled

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Active, not recruiting·DDualityBio Inc.·Phase 3·NCT06018337·541 enrolled

MEtronomic TrEatment Option in Advanced bReast cAncer

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT02954055·140 enrolled

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Terminated· Incyte logo

Incyte·Phase 2·NCT02120417·149 enrolled

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Terminated·HHoosier Cancer Research Network··NCT00235235·80 enrolled

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Unknown status·FFudan University·Phase 2·NCT04745975·100 enrolled

Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT00480597·141 enrolled

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Withdrawn·MMedstar Health Research Institute·Phase 2/3·NCT00397761

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Terminated· Novartis logo

Novartis·Phase 1/2·NCT01132664·72 enrolled

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05212454·400 enrolled

Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Completed·SSwiss Cancer Institute·Phase 1/2·NCT00003902·110 enrolled

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Completed· Gilead logo

Gilead·Phase 3·NCT03901339·543 enrolled

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Completed·SSCRI Development Innovations, LLC·Phase 1·NCT00632489·20 enrolled

Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00477464·51 enrolled

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03175666

Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

Unknown status·FFudan University·Phase 2·NCT04780347·92 enrolled

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT00829166·991 enrolled

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06797635·372 enrolled

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00468585·62 enrolled

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Active, not recruiting·EEnliven Therapeutics·Phase 1·NCT06328738·275 enrolled

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

Completed·—·Phase 1·NCT03958721·20 enrolled

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT05429684·120 enrolled

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

Completed·PPuma Biotechnology, Inc.·Phase 3·NCT01808573·621 enrolled

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT00959946·32 enrolled

Brain Metastases In ErbB2-Positive Breast Cancer

Terminated· GSK logo

GSK·Phase 2·NCT00437073·22 enrolled

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Unknown status·GGenta Incorporated·Phase 2·NCT01609127·213 enrolled

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer

Withdrawn·MMedSIR·Phase 2·NCT05227131

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Completed·CCelldex Therapeutics·Phase 2·NCT01997333·327 enrolled

Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT00429871·272 enrolled

Pancreatic Cancer16 trials

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01013649·546 enrolled

Study of Ruxolitinib in Pancreatic Cancer Patients

Completed· Incyte logo

Incyte·Phase 2·NCT01423604·136 enrolled

Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT01918644·21 enrolled

Show 13 more trials

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Active, not recruiting·UUniversity of Nebraska·Phase 2·NCT03073785·46 enrolled

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Terminated·NNewLink Genetics Corporation·Phase 3·NCT01836432·302 enrolled

Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer

Completed·CCancer Trials Ireland·Phase 2·NCT00962312·9 enrolled

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00634725·820 enrolled

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00614653·17 enrolled

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03523312·47 enrolled

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

Unknown status·SSamsung Pharmaceutical Co., Ltd.·Phase 3·NCT02854072·148 enrolled

Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer

Completed·IIRCCS San Raffaele·Phase 2/3·NCT00960284·102 enrolled

Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer

Terminated·—·Phase 1/2·NCT00889187·10 enrolled

Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·MMedical University of South Carolina·Phase 2·NCT00408564·39 enrolled

Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer

Terminated·HHerlev Hospital·Phase 2·NCT02767752·21 enrolled

GTX-RT in Borderline Resectable Pancreatic Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01754623·9 enrolled

Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer

Completed·UUniversity of Miami·Phase 2·NCT00290693·45 enrolled

Colorectal Cancer12 trials

Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT05797077·346 enrolled

Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer

Completed·UUniversity of Pittsburgh·Phase 2·NCT00177307·40 enrolled

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT01061515·21 enrolled

Show 9 more trials

Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer

Completed·AAEterna Zentaris·Phase 3·NCT01097018·468 enrolled

Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06547385·40 enrolled

Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00070265·80 enrolled

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

Completed· GSK logo

GSK·Phase 1·NCT00536809·12 enrolled

Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer

Completed·CCancer Research UK, Glasgow·Phase 3·NCT00749450·6,088 enrolled

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

Completed·HHerbert Hurwitz·Phase 2·NCT00290615·30 enrolled

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Completed· Roche logo

Roche··NCT01399190·68 enrolled

Maintenance Treatment With Capecitabine in Colorectal Cancer Patients

Unknown status·SSun Yat-sen University·Phase 2·NCT02027363·245 enrolled

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04301557·25 enrolled

Metastatic Colorectal Cancer12 trials

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT04607421·831 enrolled

Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT00254137·92 enrolled

Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 2·NCT02068131·30 enrolled

Show 9 more trials

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Active, not recruiting·AAkeso·Phase 2·NCT05382442·254 enrolled

Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT01955629·4 enrolled

Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT04310176·200 enrolled

Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Unknown status·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT04262687·55 enrolled

Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

Unknown status·—·Phase 1/2·NCT04008511·54 enrolled

Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT04534218·49 enrolled

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02780700·1 enrolled

Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Completed·SSwiss Cancer Institute·Phase 1/2·NCT00004187

Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Completed·SSwiss Cancer Institute·Phase 1/2·NCT00217711·23 enrolled

Locally-advanced Rectal Cancer9 trials

Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

Completed·UUniversity College, London·Phase 1/2·NCT00972881·82 enrolled

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543842·19 enrolled

Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer

Recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT05136326·21 enrolled

Show 6 more trials

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Recruiting·ZZhejiang University·Phase 2·NCT05731726·50 enrolled

A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

Terminated·GGeorge Albert Fisher·Phase 1/2·NCT00226941·23 enrolled

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

Not yet recruiting·TTao Zhang·Phase 3·NCT07113275·435 enrolled

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06840665·46 enrolled

Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer

Unknown status·KKing Faisal Specialist Hospital & Research Center·Phase 2·NCT02919878·25 enrolled

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

Recruiting·YYong Zhang,MD·Phase 3·NCT06017583·48 enrolled

75 more indications

Gastric Cancer8 trials

Perioperative Chemotherapy in Gastric Cancer

Terminated·UUkrainian Society of Clinical Oncology·Phase 2·NCT04937738·69 enrolled

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00678535·904 enrolled

T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy

Unknown status·—·Phase 2·NCT02250209·40 enrolled

Show 5 more trials

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Recruiting·HHallym University Medical Center·Phase 3·NCT04787354·976 enrolled

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

Unknown status·PProfessor David Cunningham·Phase 2/3·NCT00450203·1,103 enrolled

Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer

Unknown status·TTianshu Liu·Phase 2·NCT02623153·200 enrolled

A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06555471·40 enrolled

Docetaxel and Capecitabine in Advanced Gastric Cancer

Completed·—·Phase 2·NCT00142038·80 enrolled

Capecitabine7 trials

S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.

Completed·DDutch Colorectal Cancer Group·Phase 3·NCT01918852·161 enrolled

Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC

Not yet recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06699459·76 enrolled

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Terminated·FFox Chase Cancer Center·Phase 2·NCT00321100·23 enrolled

Show 4 more trials

Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor

Completed·—·Phase 1·NCT00005839

CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)

Not yet recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2·NCT07254962·75 enrolled

Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01213238·116 enrolled

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03448835·20 enrolled

Esophageal Cancer4 trials

A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer

Completed·CCancer Trials Ireland·Phase 2·NCT01710592·35 enrolled

Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence

Unknown status·TThe First Affiliated Hospital of Henan University of Science and Technology·Phase 3·NCT04404491·240 enrolled

Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation

Unknown status·LLisette Nixon·Phase 2/3·NCT02741856·584 enrolled

Show 1 more trial

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04615013·24 enrolled

Rectal Cancer4 trials

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1/2·NCT03770689·19 enrolled

Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer

Completed·RRadboud University Medical Center·Phase 2·NCT01273051·55 enrolled

Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT07068763·52 enrolled

Show 1 more trial

Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT01060007·80 enrolled

Chemotherapy3 trials

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors

Active, not recruiting·CCentre Oscar Lambret·Phase 1/2·NCT03585465·63 enrolled

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01677884·10 enrolled

Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05307198·38 enrolled

Adenocarcinoma3 trials

XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach

Unknown status·HHarbin Medical University·Phase 2·NCT01798251·40 enrolled

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01208103·30 enrolled

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Terminated· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04675983·36 enrolled

Locally Advanced Colon Cancer2 trials

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 3·NCT07132008·94 enrolled

Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06790212·168 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT02335411·318 enrolled

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·BBeijing Biostar Pharmaceuticals Co., Ltd.·Phase 2/3·NCT06841679·778 enrolled

Kidney Cancer2 trials

Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00042965·60 enrolled

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00121251·17 enrolled

Advanced Solid Tumors2 trials

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT04047862·446 enrolled

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06544655·213 enrolled

Pancreatic Neuroendocrine Tumor2 trials

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT05247905·31 enrolled

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

Terminated·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT02736448·35 enrolled

Gastroesophageal Junction Carcinoma2 trials

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Completed· BeiGene logo

BeiGene·Phase 3·NCT03777657·997 enrolled

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

Terminated·UUniversity of California, Irvine·Phase 2·NCT00256321·4 enrolled

Nasopharyngeal Carcinoma2 trials

Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT02633176·120 enrolled

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT05201859·150 enrolled

Cholangiocarcinoma2 trials

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00033540·57 enrolled

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Terminated·SStanford University·Phase 2·NCT01151761·2 enrolled

Gastroesophageal Junction2 trials

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00891878·12 enrolled

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00054457·46 enrolled

Radiation Therapy2 trials

Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00745134·22 enrolled

Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer

Unknown status·LLoma Linda Oncology Medical Group, Inc.·Phase 2·NCT00967655·54 enrolled

Patients With Advanced Solid Tumors2 trials

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

Completed·SSCRI Development Innovations, LLC·Phase 1·NCT01226732·23 enrolled

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00006465·22 enrolled

First-line Treatment2 trials

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07117435·7 enrolled

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07383285·106 enrolled

Neoadjuvant Therapy2 trials

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06245889·30 enrolled

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06992336·411 enrolled

Advanced1 trial

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 1·NCT02892123·279 enrolled

Toxicity1 trial

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Active, not recruiting·UUniversity of Cincinnati·Phase 2/3·NCT05902533·33 enrolled

Squamous Cell Cancer of the Head and Neck1 trial

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Completed·—·Phase 2·NCT01044433·44 enrolled

Prostate Cancer1 trial

Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00151047·15 enrolled

Patients With Solid Tumors1 trial

Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors

Completed·DDorte Nielsen·Phase 1·NCT03295084·39 enrolled

Advanced Solid Tumours1 trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05489211·454 enrolled

Metastatic Biliary Tract Carcinoma1 trial

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not yet recruiting·BBa Yi·Phase 2·NCT06430827·20 enrolled

Hepatocellular Cancer1 trial

A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

Terminated·—·Phase 2·NCT03026803·4 enrolled

Triple-Negative Breast Cancer1 trial

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Recruiting·SStanford University·Phase 2·NCT04768426·40 enrolled

Anal Cancer1 trial

Adaptive Radiation in Anal Cancer

Recruiting·—·N/A·NCT05838391·20 enrolled

Elderly Patients1 trial

Cetuximab for Elderly Patients With mCRC

Terminated·SSwiss Cancer Institute·Phase 2·NCT01718808·24 enrolled

Cervical Cancer1 trial

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00016926

Intestinal Cancer1 trial

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT02024607·495 enrolled

Advanced Malignant Solid Tumors1 trial

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06446388·360 enrolled

Colon Cancer1 trial

Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery

Unknown status·UUniversity of Birmingham·Phase 2/3·NCT00647530·1,053 enrolled

Metastatic Tumors1 trial

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT02794571·518 enrolled

Primary Peritoneal Cancer1 trial

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004012

Squamous Cell Carcinoma1 trial

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Terminated·UUniversity of Nebraska·Phase 2·NCT02524275·14 enrolled

Esophageal Adenocarcinoma1 trial

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT03929666·74 enrolled

Colon Cancer Stage III1 trial

Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III

Completed·OOslo University Hospital·Phase 2·NCT02978612·170 enrolled

Stomach Cancer1 trial

Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00411229·1,035 enrolled

Nausea and vomiting1 trial

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT01534637·22 enrolled

Pancreatic Adenocarcinoma1 trial

Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma

Completed·—·Phase 4·NCT00854477·13 enrolled

Neoadjuvant Treatment1 trial

Neoadjuvant Treatment of Colon Cancer

Completed·VVejle Hospital·Phase 2·NCT01108107·76 enrolled

Immunotherapy1 trial

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT05555888·34 enrolled

Chemoradiation1 trial

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT06210971·60 enrolled

Vinorelbine1 trial

Lapatinib in Combination With Vinorelbine

Completed· Novartis logo

Novartis·Phase 2·NCT01013740·112 enrolled

Neuroendocrine Cancer1 trial

Capecitabine and Temozolomide for Neuroendocrine Cancers

Completed·—·Phase 2·NCT00869050·41 enrolled

Adjuvant Chemotherapy1 trial

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT04803539·260 enrolled

Locally Advanced Cancer1 trial

Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT00086931·37 enrolled

Patients With Locally Advanced Rectal Cancer1 trial

Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT00084591

Adjuvant Therapy1 trial

A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

Recruiting·SSun Yat-sen University·Phase 3·NCT03561740·794 enrolled

Renal Cell Carcinoma1 trial

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00496587·34 enrolled

Rectal Adenocarcinoma1 trial

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02935309·20 enrolled

Neuroendocrine Tumor1 trial

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02831179

Malignant Mesothelioma1 trial

Capecitabine in Treating Patients With Malignant Mesothelioma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00004183·27 enrolled

Metastatic Nasopharyngeal Cancer1 trial

A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

Completed· Roche logo

Roche·Phase 2·NCT02608073·45 enrolled

Organ Preservation1 trial

Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)

Recruiting·NNeil Kopek·Phase 2·NCT06991465·35 enrolled

Chemoradiotherapy1 trial

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT02010567·32 enrolled

Metastatic Prostate Cancer1 trial

Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00258284·30 enrolled

Total Neoadjuvant Therapy1 trial

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Not yet recruiting·FFudan University·Phase 2·NCT06390982·46 enrolled

Malignancies1 trial

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Recruiting·AALX Oncology Inc.·Phase 1/2·NCT07007559·80 enrolled

Biliary Tract Carcinoma1 trial

A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

Unknown status·FFudan University··NCT04856761·160 enrolled

Carcinoma of Unknown Primary1 trial

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00148135

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Neoadjuvant Immunotherapy1 trial

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05914389·100 enrolled

Metastatic1 trial

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00755534·68 enrolled

Conversion Therapy1 trial

Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT06949111·128 enrolled

Gastroesophageal Junction Cancer1 trial

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01123473·29 enrolled

Gallbladder Cancer1 trial

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02042443·53 enrolled

Colorectal Adenocarcinoma1 trial

Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

Withdrawn·FFujian Cancer Hospital·Phase 3·NCT03708536

Liver Cancer1 trial

Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer

Terminated·UUniversity of Washington·Phase 2·NCT00787787·41 enrolled

Locally Advanced1 trial

Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00658593·19 enrolled

Rectal Cancer Patients1 trial

Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients

Completed·CChinese Academy of Medical Sciences·Phase 1·NCT01268943·18 enrolled

Gastric Carcinoma1 trial

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Completed·SStanford University·Phase 2·NCT00780494·35 enrolled

Unspecified1 trial

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Recruiting·SSonya Reid·Phase 2·NCT05693766·64 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 30, 1998

XELODA

NDA NDA020896

Sources

References

[1]
ClinicalTrials.gov — 1334 trial records for Capecitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Capecitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Capecitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020896). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Engelhard Arzneimittel GmbH & Co.KG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Thymidylate Synthase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEngelhard Arzneimittel GmbH & Co.KG